Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 16.34 | 6.40 | 4.43 | 7.62 | 8.72 | 6.75 | 6.47 | 5.10 | 5.43 | 7.07 | 6.66 | 5.76 | 5.43 | 2.87 | 3.13 | 2.83 | 2.95 | 2.80 | 3.63 | 3.30 | 8.29 |
| — | -5.3% | -31.6% | +49.4% | +60.6% | -4.5% | -2.9% | -11.5% | +0.1% | +146.2% | +113.1% | +103.6% | +84.2% | +2.6% | -13.9% | -14.2% | -64.5% | -57.2% | -74.9% | -73.7% | -73.0% | |
| P/B Ratio | — | — | — | — | — | — | — | — | 21.45 | 20.38 | — | — | — | — | — | — | — | — | — | 25.36 | 11.94 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +512.3% | +238.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 2607.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.7% | 90.9% | 91.9% | 91.3% | 88.1% | 85.3% | 88.5% | 89.9% | 90.3% | 89.8% | 90.8% | 90.3% | 88.6% | 88.4% | 86.8% | 87.5% | 87.5% | 88.9% | 88.8% | 90.2% | 89.0% |
| — | +6.6% | +3.8% | +1.5% | -2.4% | -5.0% | -2.5% | -0.4% | +1.8% | +1.5% | +4.6% | +3.2% | +1.4% | -0.5% | -2.2% | -3.0% | -1.8% | -0.2% | +0.8% | -1.8% | -2.2% | |
| Operating Margin | -113.7% | 0.2% | -39.8% | -50.5% | -99.7% | -171.2% | -182.3% | -112.6% | -69.6% | -118.3% | -137.1% | -62.1% | -64.7% | -72.8% | -128.2% | -112.1% | -112.4% | -112.7% | -161.9% | -123.1% | -206.5% |
| — | +100.1% | +78.2% | +55.1% | -43.2% | -44.7% | -33.0% | -81.3% | -7.5% | -62.5% | -6.9% | +44.6% | +42.4% | +35.4% | +20.8% | +9.0% | +45.6% | +35.6% | +53.6% | +64.0% | +75.5% | |
| Net Margin | -139.8% | -19.8% | -46.3% | -69.7% | -121.3% | -206.2% | -216.5% | -152.7% | -93.9% | -152.9% | -171.9% | -110.6% | -104.9% | -114.2% | -175.7% | -159.6% | -160.5% | -160.8% | -209.3% | -175.9% | -266.2% |
| — | +90.4% | +78.6% | +54.4% | -29.2% | -34.9% | -25.9% | -38.1% | +10.5% | -33.9% | +2.2% | +30.7% | +34.6% | +29.0% | +16.0% | +9.3% | +39.7% | +20.1% | +39.6% | +54.1% | +68.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | -448.9% | -84.8% | -110.2% | — | — | — | — | — | — | — | — | — | -142.4% | -68.8% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -406.0% | -214.2% | |
| ROA | -63.1% | -5.7% | -10.4% | -13.7% | -16.9% | -21.9% | -16.4% | -12.8% | -8.1% | -13.8% | -17.0% | -14.0% | -15.1% | -23.2% | -24.3% | -21.9% | -18.8% | -17.1% | -19.9% | -22.4% | -21.0% |
| — | +74.1% | +36.9% | -7.1% | -108.8% | -58.1% | +3.5% | +8.7% | +46.4% | +40.2% | +29.9% | +36.0% | +19.5% | -35.4% | -22.2% | +2.3% | +10.2% | +18.0% | +15.9% | +4.0% | -9.4% | |
| ROIC | — | — | — | — | — | — | — | — | -58.4% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | 4.78 | 3.24 | — | — | — | — | — | — | — | — | — | 0.05 | 0.02 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +204.5% | -23.6% | |
| Debt / EBITDA | — | 1037.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.01 | 3.80 | 4.69 | 4.01 | 3.99 | 4.14 | 5.65 | 6.01 | 9.00 | 8.15 | 7.47 | 5.42 | 7.06 | 3.04 | 3.80 | 5.39 | 6.40 | 7.74 | 8.41 | 5.11 | 6.32 |
| — | -8.2% | -17.0% | -33.3% | -55.7% | -49.2% | -24.4% | +10.9% | +27.4% | +168.2% | +96.4% | +0.6% | +10.3% | -60.7% | -54.8% | +5.5% | +1.3% | +5.0% | +53.6% | -5.2% | -13.9% | |
| Quick Ratio | 3.65 | 3.41 | 4.28 | 3.65 | 3.79 | 3.99 | 5.47 | 5.81 | 8.77 | 7.93 | 7.20 | 5.24 | 6.87 | 2.85 | 3.59 | 5.21 | 6.14 | 7.46 | 8.16 | 4.90 | 6.13 |
| — | -14.7% | -21.8% | -37.1% | -56.8% | -49.7% | -24.0% | +10.9% | +27.7% | +178.2% | +100.6% | +0.6% | +11.8% | -61.8% | -56.0% | +6.4% | +0.3% | +3.7% | +54.6% | -7.7% | -15.7% | |
| Interest Coverage | -4.08 | -0.78 | -2.26 | -1.76 | -3.30 | -5.63 | -9.68 | -6.82 | -5.49 | -8.64 | -9.86 | -2.19 | -3.30 | -5.40 | -7.50 | -3.01 | -8.33 | -8.30 | -98.53 | -2.68 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying URGN stock.
UroGen Pharma Ltd.'s current P/E is -11.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
UroGen Pharma Ltd.'s current operating margin is -113.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking UroGen Pharma Ltd.'s business trajectory between earnings reports.